Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 2Wilms Tumor 1Multiple Myeloma 1Hematologic Neoplasms 1Heart Diseases 1Cardiotoxicity 1

Interventions

Antineoplastic Agents 3Nutrition Assessment 2Mass Screening 2Echocardiography 2Blood Specimen Collection 2liposomal doxorubicin 1Vitamin E 1Vitamin D 1Vital Signs 1Tomography, X-Ray Computed 1Tomography, Emission-Computed 1Therapeutics 1Surveys and Questionnaires 1Specimen Handling 1Progestins 1Positron-Emission Tomography 1Methods 1Magnetic Resonance Imaging 1Interviews as Topic 1Immunomodulating Agents 1Immune Checkpoint Inhibitors 1Hormone Replacement Therapy 1Hematologic Tests 1Exercise Test 1Estrogens 1Estrogen Replacement Therapy 1Educational Status 1Dietary Supplements 1Diet, Fat-Restricted 1Diagnosis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Heart Diseases × Immunomodulating Agents × Clear all
NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

Completed
500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡